ENDONOVO THERAPEUTICS, INC. Stockholders Equity

Quick Answer

ENDONOVO THERAPEUTICS, INC. reported Stockholders Equity of -$32.18 million for fiscal year 2022.

ENDONOVO THERAPEUTICS, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2022 -$32.18M -104.0%
2021 -$15.77M -9.7%
2020 -$14.37M +29.9%
2019 -$20.50M -80.0%
2018 -$11.39M -19.3%
2017 -$9.55M -11.5%
2016 -$8.56M +7.7%
2015 -$9.28M -97.7%
2014 -$4.69M -13.6%
2013 -$4.13M -5842.2%
2011 $72.0K -56.7%
2010 $166.1K -29.5%
2009 $235.4K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2023 -$22.96M -17.1% -2.4%
June 30, 2023 -$22.41M -17.0% +8.0%
March 31, 2023 -$24.37M -35.1% +24.3%
December 31, 2022 -$32.18M -104.0% -64.1%
September 30, 2022 -$19.61M -7.6% -2.3%
June 30, 2022 -$19.16M -12.8% -6.2%
March 31, 2022 -$18.04M -12.9% -14.3%
December 31, 2021 -$15.77M -9.7% +13.4%
  • ENDONOVO THERAPEUTICS, INC. showed a decrease of -104.0% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2009–2022 period, ENDONOVO THERAPEUTICS, INC.’s stockholders equity has declined by 13767.6% (from $235.4 thousand to -$32.18 million).
  • The most recent figure is from ENDONOVO THERAPEUTICS, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 17, 2023.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment